VALID Accommodations for Academic Medical Centers and Other Lab Tests

The U.S. Supreme Court recently marked a significant shift in the tariff landscape, learn what that means for your organization.

 WASHINGTON—AdvaMed, the Medtech Association, the largest trade association representing medtech innovators, thanked President Trump and Congress for enacting the Small Business Innovation and Economic Security Act (S. 3971). Signed into law, the legislation reauthorizes the federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.

“The Insight Series: AI & Digital Health” features industry experts answering key questions to help inform policymakers and the public about how AI is shaping the future of care delivery. Our latest edition features Julia Strandberg, Executive Vice President, Chief Business Leader, Connected Care at Philips.

WASHINGTON—AdvaMed, the Medtech Association, today applauded House of Representatives passage of S. 3971, the Small Business Innovation and Economic Security Act, legislation reauthorizing the federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. House passage follows Senate passage earlier this month, bringing the restoration of these initiatives one step closer to completion.  

WASHINGTON—AdvaMed® announced today that nominations for its 2025 Lifetime Achievement Award as well as the AdvaMedDx Lifetime of Leadership & Service Award and theAdvaMed® Imaging Röntgen Award are open through April 10. All three of these annual awards will be presented during The MedTech Conference, Oct.18-21, 2026, in Boston. 

TORONTO and DALLAS, March 3, 2026 /PRNewswire/ – Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (“Perimeter” or the “Company”), a commercial-stage medical technology company, announced today that it has received U.S. Food and Drug Administration (“FDA”) premarket approval (“PMA”) for Claire™ (formerly the Perimeter OCT B-Series with ImgAssist AI 2.0), the first AI-enabled imaging device approved in the United States for intraoperative breast cancer margin assessment. The technology received Breakthrough Device designation from the FDA and is designed to enhance surgeons’ ability to detect difficult-to-see cancer during breast-conserving surgery and potentially reduce the need for re-operations.

AdvaMed® 2025 Membership Has Its Privileges highlights major legislative and regulatory wins delivering millions in savings and new revenue for members.

Medicare breakthrough medical technologies face delays between FDA authorization and coverage decisions, slowing patient access to innovation.